Resources Repository
-
ArticlePublication 2017Cost-Effectiveness of Testing and Treatment for Latent TB
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve …
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve TB elimination in the United States. This analysis estimated health outcomes, costs, and cost-effectiveness of LTBI testing and treatment among non-US born residents with and without medical comorbidities (e.g., diabetes, HIV infection, and end-stage renal disease). A decision analytic tree and Markov cohort simulation model was used to compare the following strategies: no testing, tuberculin skin test (TST), interferon gamma release assay…
Microsimulation | State-Transition | Health/Medicine | Global | Test Performance | Cost-Effectiveness Analysis | Infectious Diseases | Chronic Disease/Risk | Health Systems | Economics/Finance | North America -
ArticlePublication 2017Likelihood Approach for Calibration of Stochastic Epidemic Models
Stochastic transmission dynamic models are especially useful for studying the early emergence of novel pathogens …
Stochastic transmission dynamic models are especially useful for studying the early emergence of novel pathogens given the importance of chance events when the number of infectious individuals is small. However, methods for parameter estimation and prediction for these types of stochastic models remain limited. This paper describes a calibration and prediction framework for stochastic compartmental transmission models of epidemics. The proposed method applies a linear noise approximation to describe the size of the fluctuations, and…
Dynamic Simulation | Calibration/Validation | Health/Medicine | Global | Dynamic Transmission | Infectious Diseases | Health Systems -
OrganizationWeb Portal 2024PATH
PATH is an international nonprofit organization that has been translating ideas into health solutions for …
PATH is an international nonprofit organization that has been translating ideas into health solutions for 40 years, with a focus on child survival, maternal and reproductive health, and infectious diseases. PATH mobilizes partners around the world in order to take innovation to scale, working alongside countries primarily in Africa and Asia to tackle their greatest health needs. PATH takes a multidimensional approach to solving health challenges, with work spanning five platforms: Vaccines to give children a…
Health Outcomes | Health/Medicine | Sub-Saharan Africa | Global | Costing Methods | Cost-Effectiveness Analysis | Technology Assessment | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Social Determinants | Health Systems | Asia & Pacific -
OrganizationWeb Portal 2024One Health Trust
One Health Trust, formally the Center for Disease Dynamics, Economics & Policy (CDDEP), was founded …
One Health Trust, formally the Center for Disease Dynamics, Economics & Policy (CDDEP), was founded with the objective of using research to support better decision-making in health policy. One Health Trust researchers employ a range of expertise—including economics, epidemiology, disease modeling, risk analysis, and statistics—to conduct actionable, policy-oriented research on malaria, antibiotic resistance, disease control priorities, environmental health, alcohol and tobacco, and other global health priorities. One Health Trust projects are global in scope, spanning…
Health Outcomes | Health/Medicine | Sub-Saharan Africa | Global | Costing Methods | Mathematical Models | Cost-Effectiveness Analysis | Technology Assessment | Infectious Diseases | Chronic Disease/Risk | Social Determinants | Environmental Health | Policy/Regulation | Climate/Environment | Economics/Finance | Asia & Pacific -
OrganizationWeb Portal 2024ISPOR
Founded in 1995 as an international multidisciplinary professional membership society, the International Society for Pharmacoeconomics …
Founded in 1995 as an international multidisciplinary professional membership society, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) exists to advance the policy, science, and practice of pharmacoeconomics (health economics) and health outcomes research. ISPOR publishes Value in Health, which contains original research articles in the areas of economic evaluation, outcomes research, and conceptual, methodological, and health policy articles. Beyond health economics and outcomes research resources, tools of ISPOR include strategic initiatives, publications, and member…
Preferences/Values | Health Outcomes | Health/Medicine | Global | Priority Setting/Ethics | Costing Methods | Value of Information | Mathematical Models | Cost-Effectiveness Analysis | Technology Assessment | Operations Research | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Health Systems | Policy/Regulation | Business/Industry | Economics/Finance | Science/Technology -
OrganizationWeb Portal 2024ISOQOL
The International Society for Quality of Life Research (ISOQOL), established in 1993, is a non-profit …
The International Society for Quality of Life Research (ISOQOL), established in 1993, is a non-profit society to advance the scientific study of health-related quality of life and other patient-centered outcomes to identify effective interventions, enhance the quality of health care and promote the health of populations. ISOQOL provides a networking opportunity for those in the quality of life research field. ISOQOL fosters exchange of information through: scientific publications, international conferences, educational short-courses and online webinars, and collaborative…
Preferences/Values | Health Outcomes | Health/Medicine | Global -
ArticlePublication 2013Validation and Calibration of a Simulation Model of Pediatric HIV Infection
The authors developed a microsimulation model of pediatric HIV disease progression using the Cost-Effectiveness of …
The authors developed a microsimulation model of pediatric HIV disease progression using the Cost-Effectiveness of Preventing AIDS Complications (CEPAC) model framework. This CEPAC-Pediatric model was then validated by varying CD4 data and comparing the corresponding model-generated survival curves to empirical survival curves obtained from the International Epidemiologic Database to Evaluate AIDS (IeDEA). The model was calibrated to other African countries by systematically varying immunologic and HIV mortality-related input parameters. In the calibration analyses, the model-generated…
Microsimulation | Calibration/Validation | Health/Medicine | Sub-Saharan Africa | Infectious Diseases | Child/Nutrition -
ArticlePublication 2012Health and Economic Outcomes of Interventions to Reduce Pregnancy-Related Mortality in Nigeria
This paper examines the cost-effectiveness and impact of individual and integrated packages of interventions aimed …
This paper examines the cost-effectiveness and impact of individual and integrated packages of interventions aimed to reduce maternal mortality in Nigeria, a country with extremely high maternal mortality rates. Using a previously validated model adapted to the Nigerian context, the study finds that an increase of access to family planning is the most effective individual strategy, which not only reduces pregnancy-related mortality but also proves to be economically efficient. However, relying solely on family planning…
State-Transition | Health Outcomes | Health/Medicine | Sub-Saharan Africa | Cost-Effectiveness Analysis | Maternal/Reproductive Health | Health Systems | Policy/Regulation | Economics/Finance -
ArticlePublication 2011Health and Economic Impact of HPV 16/18 Vaccination and Cervical Cancer Screening in Eastern Africa
In this article the authors use epidemiologic data from Kenya, Mozambique, Tanzania, Uganda, and Zimbabwe …
In this article the authors use epidemiologic data from Kenya, Mozambique, Tanzania, Uganda, and Zimbabwe to develop models of HPV-related infection and disease. For each country, they assessed HPV vaccination of girls before age 12 followed by screening with HPV DNA testing once, twice, or three times per lifetime (at ages 35, 40, 45). For women over age 30, they assessed only screening (with HPV DNA testing up to three times per lifetime or VIA…
Microsimulation | Calibration/Validation | Health/Medicine | Sub-Saharan Africa | Cost-Effectiveness Analysis | Infectious Diseases | Chronic Disease/Risk | Clinical Care | Economics/Finance | Science/Technology